Karuna Therapeutics Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
136 / 1361
Position in country
2356 / 14179
Return on Assets, %
-30.9
-40.3
Debt to Equity, %
0
3.2
Intangible assets and goodwill, %
0
0.2
Total Equity change 1Y, %
11.3
-9
Revenue Y, % chg
-93.9
0
P/BV
10
1.8
EV/EBITDA
-21.8
-1.6
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Karuna Therapeutics Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
12599.2
Ticker
KRTX.O
ISIN
US48576A1007
IPO date
Availability on Russian exchanges
Yes
Reporting for
2024-02-22
Date fact. publication of reports
2023-12-31
Company Description
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: